Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.
Screening for deadly illnesses does not necessarily save lives despite assumptions otherwise, according to a study published in the International Journal of Epidemiology.
The authors examined the results of screening for 19 diseases to determine whether or not screening actually helped to prevent death. Patients were asymptomatic when tested. They found that, screening decreases mortality in only a few circumstances.
“Screening for diseases that can lead to death typically does not prolong life substantially,” John Ioannidis, MD, DSc, the C.F. Rehnborg Professor in Disease Prevention at Stanford and senior author of the study, said in a statement. “A few screening tests may avert some deaths caused by the disease being screened, but even then it is difficult to document an improvement in overall survival.”
When choosing diseases to study, the researchers focused on cancer and heart and vascular diseases, as well as type 2 diabetes mellitus and chronic obstructive pulmonary disease, because mortality is a common outcome for these diseases. Diseases/disorders they did not include fell into the following clinical categories: infectious diseases; mental health conditions and substance abuse; metabolic, nutritional and endocrine disorders (except type 2 diabetes); musculoskeletal disorders; injury and violence; vision and hearing disorders; obstetric and gynaecological conditions; and miscellaneous (except chronic obstructive pulmonary diseases).
The only tests that reduced the number of deaths caused by the diseases studied were ultrasound for abdominal aortic aneurysm in men, mammography for breast cancer, and fecal occult blood test and flexible sigmoidoscopy for colorectal cancer.
The authors conjecture that the tests that failed to reduce mortality may not be able to detect the early stages of a disease accurately enough. Another factor may be the availability of life-saving treatments.
However, even if screening does not save lives, it might ward off other ill effects of disease, according to Dr Ioannidis.
“Screening may still be highly effective (and thus justifiable) for a variety of other clinical outcomes, besides mortality,” the authors concluded in their paper. "However, our overview suggests that expectations of major benefits in mortality from screening need to be cautiously tempered.”
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
NCCN Data Find Racial, Socioeconomic Disparities in Quality of Care for Metastatic Pancreatic Cancer
April 9th 2025New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with metastatic pancreatic cancer are less likely to receive recommended treatments and achieve longer survival.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen